AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders
A new clinical trial is evaluating upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab.
| Drug | MOA / Company | Stage |
|---|---|---|
| dupilumab | AbbVie | Lead |
| upadacitinib | — | Competing |
Focal Asset
dupilumab
Company
AbbVie
Indication
Dermatology / Atopic Dermatitis
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
If successful, this trial could expand AbbVie's market share in atopic dermatitis and challenge the current standard of care represented by dupilumab.
Why it matters
The ongoing trial of upadacitinib for patients inadequately responding to dupilumab could significantly alter the competitive landscape in the atopic dermatitis market. Success in this trial may enhance AbbVie's market position and challenge the current standard of care, necessitating close observation of trial outcomes.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress and interim results from the trial, particularly the EASI response rates in participants.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.